All In Biotech

NDA 209521 · Almirall

Seysara

Sarecycline Hydrochloride · Oral

Novel

Last checked: Nov 20, 2026Latest source record: Mar 30, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Oct 1, 2018

Approved uses

1

Original approval plus efficacy supplements

Registered trials

8

3 Phase 3, 1 recruiting

FAERS reports

200

39 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 5, 2024.

SEYSARA ® (sarecycline) tablet, is indicated for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older. Limitations of Use Efficacy of SEYSARA beyond 12 weeks and safety beyond 12 months have not been established. SEYSARA has not been evaluated in the treatment of infections [see Clinical Studies ( 14 )] . To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, SEYSARA should be used only as indicated [see Warnings and Precautions ( 5.6 )] . SEYSARA ® is a tetracycline-class drug indicated for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older. ( 1 ) Limitations of Use Efficacy of SEYSARA beyond 12 weeks and safety beyond 12 months have not been established. SEYSARA has not been evaluated in the treatment of infections. To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, SEYSARA should be used only as indicated [see Warnings and Precautions ( 5.6 )].

Mechanism: Sarecycline is an aminomethylcycline within the tetracycline class of drugs. [see CLINICAL PHARMACOLOGY ( 12.4 )] . The mechanism of action of SEYSARA in treating the inflammatory lesions of non-nodular acne vulgaris is not known.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 1, 2018 Original approval · Type 1 - New Molecular Entity NovelLetterLabelReview
3 products under this application
  • SEYSARA · SARECYCLINE HYDROCHLORIDE EQ 100MG BASE · TABLET, ORAL · Prescription
  • SEYSARA · SARECYCLINE HYDROCHLORIDE EQ 150MG BASE · TABLET, ORAL · Prescription
  • SEYSARA · SARECYCLINE HYDROCHLORIDE EQ 60MG BASE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Sarecycline" as an intervention, any sponsor and status, largest first.

All 8 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • headache24
  • drug ineffective14
  • dizziness13
  • vision blurred11
  • rash9
  • off label use8
  • product dose omission issue8
  • pruritus8
  • condition aggravated7
  • fatigue7
  • nausea7
  • anxiety6

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201935
202027
202124
202221
202323
202430
202512
202628

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Seysara (Sarecycline HCl)

2024 spending

$786K

Beneficiaries

200

637 claims

Per beneficiary

$3,929

$33.78 per unit

View as table
YearSpending
2020$163,508
2021$417,016
2022$535,840
2023$657,586
2024$785,827

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 8 on PubMed

Sponsor: Almirall

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.